Study evaluating 29 patients with symptoms that persisted for at least 4 weeks after #COVID19 showed:
-had reported fatigue, muscle pain, dyspnea, inappropriate tachycardia, and low-grade fever
-previous #COVID19 was mild in 55% of the cases
-13 patients (45%) had positive plasma RT-PCR results and 51% were positive in at least one RT-PCR sample (plasma, urine, or stool)
-18 patients (62%) received antiviral treatment.
Conclusion: #COVID19 patients with persistent symptoms, 45% of them have detectable plasma #SARSCoV2#RNA
Thank you to our Keynote Speakers from COAST-to-COAST for their insightful presentations & to the 8,752 participants who attended @MedNewsWeek Conference in February 2022. It was a pleasure learning from everyone.
Study looking at the impact of vaccine misinformation found:
-66% of U.S. adults say they would be likely to recommend vaccinating a hypothetical 5-11 yr olds in their household who is eligible for the #Covid19#vaccine.
-39% of the vaccinated-but-not-boosted hold high levels of misinformation about the effects and safety of #vaccines
-the more that unvaccinated adults worry about getting #long#Covid, the more likely they are to say they will get vaccinated
-40% of the #unvaccinated – or 9% of the total survey sample – are potentially persuadable to be #vaccinated
-long-term partial reprogramming led to rejuvenating effects in different tissues, such as the #kidney & #skin, and at the #organismal level; duration of the treatment determined the extent of the beneficial effects.
A discussion about Gastroenterology & the latest developments chronic diarrheal syndrome from one of GI’s global leaders-- Dr. Paul Feuerstadt from @Yale (@DrPaulGastro)
A discussion about Gastroenterology & the latest developments chronic diarrheal syndrome from one of GI’s global leaders-- Dr. Paul Feuerstadt from @Yale (@DrPaulGastro)
MedNews Week Conference - Infectious Disease & Gastroenterology - Dr. Paul Feuerstadt (Yale) twitter.com/i/broadcasts/1…
Happening now!
A discussion about Gastroenterology & the latest developments chronic diarrheal syndrome from one of GI’s global leaders-- Dr. Paul Feuerstadt from @Yale (@DrPaulGastro)